Alexion Pharmaceuticals Inc. Release: Researchers to Present Clinical Trial Data With Soliris® (eculizumab) Treatment in Both Approved Indications – PNH and aHUS – at American Society of Hematology Annual Meeting

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that researchers will present data from clinical studies of Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening and ultra-rare diseases caused by chronic uncontrolled complement activation, at the 55th Annual Meeting of the American Society of Hematology (ASH). Soliris is the first and only approved treatment for PNH and aHUS.

Help employers find you! Check out all the jobs and post your resume.